A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
← catalyst calendarNCT07223723 · readout in 279 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
12estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-11 | actual | When the study began enrolling |
| Primary completion | 2027-05-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Amyotrophic Lateral Sclerosis
Intervention
- Drug: Tofersen — also filed as BIIB067, QALSODY
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From Screening up to end of study follow-up (up to 52 weeks)
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed